Appendix B: Provincial Case Definitions for Diseases of Public Health Significance

Disease: Giardiasis

Effective: February 2019
Giardiasis

1.0 Provincial Reporting
Confirmed and probable cases of disease

2.0 Type of Surveillance
Case-by-case

3.0 Case Classification

3.1 Confirmed Case
Laboratory confirmation of infection, with clinically compatible signs and symptoms, from an appropriate clinical specimen (e.g., stool, duodenal fluid, small bowel biopsy):
- Demonstration of *Giardia lamblia* (*G. lamblia*) cysts or trophozoites
  OR
- Demonstration of *G. lamblia* antigen by an approved method (e.g., enzyme immunoassay [EIA], immunochromatographic test [ICT])
  OR
- Detection of Giardia deoxyribonucleic acid (DNA)

3.2 Probable Case
Clinically compatible signs and symptoms in a person with an epidemiologic link to a laboratory-confirmed case.

4.0 Laboratory Evidence

4.1 Laboratory Confirmation
Any of the following will constitute a confirmed case of Giardiasis:
- Positive for *G. lamblia* cysts or trophozoites
- Positive for *G. lamblia* antigen
- Positive for *Giardia* DNA

4.2 Approved/Validated Tests
- Microscopy/Direct Fluorescent Antibody (DFA)
- Giardia immunoassays (EIA, ICT)
- Nucleic acid amplification test (NAAT) for Giardia
4.3 Indications and Limitations
Not applicable

5.0 Clinical Evidence
Clinically compatible signs and symptoms are characterized by diarrhea, pale greasy stool, abdominal cramps, bloating, weight loss, fatigue or malabsorption of fats.

6.0 ICD 10 Code(s)
A07.1 Giardiasis (lambliaisis)

7.0 Sources


### 8.0 Document History

#### Table 1: History of Revisions

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Document Section</th>
<th>Description of Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2014</td>
<td>General</td>
<td>New template. Section 8.0 title changed from “References” to “Sources”. Sections 9.0 Document History Added.</td>
</tr>
<tr>
<td>December 2014</td>
<td>Case Definition Title</td>
<td>Case Definition title updated to remove “except asymptomatic cases”.</td>
</tr>
<tr>
<td>December 2014</td>
<td>3.1 Confirmed Case</td>
<td>First sentence “with clinically compatible signs and symptoms…” revised to “with or without clinically compatible signs and symptoms…”</td>
</tr>
<tr>
<td>December 2014</td>
<td>4.2 Approved/Validated Tests</td>
<td>First bullet, “DFA” revised to “Direct Fluorescent Antibody (DFA)”.</td>
</tr>
<tr>
<td>December 2014</td>
<td>8.0 Sources</td>
<td>All sources updated.</td>
</tr>
<tr>
<td>February 2019</td>
<td>General</td>
<td>Minor revisions were made to support the regulation change to Diseases of Public Health Significance</td>
</tr>
</tbody>
</table>
| April 2019      | 3.1 Confirmed Case                | First sentence to “with or without clinically compatible signs and symptoms…” revised to “with clinically compatible signs and symptoms…” to align with Disease of Public Health Significance  
Addition of “Detection of Giardia deoxyribonucleic acid DNA”                                                                                     |
|                 | 4.0 Laboratory Evidence           | 4.1 Laboratory Confirmation  
Addition of “Positive for Giardia DNA”  
4.2 Approval/Validated Tests  
Addition of “Nucleic acid amplification test (NAAT) for Giardia”                                                                                     |